-
Company Profile
Ocular Therapeutix Inc – Company Profile
Ocular Therapeutix Inc (Ocular Therapeutix) is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammation and pain. Its pipeline products include OTX-TP, used for treating glaucoma and ocular hypertension, OTX-BPI, targeting acute ocular pain, OTX-BDI, against post-op pain, inflammation and anti-bacterial infections; OTX-KTO for treating allergic conjunctivitis; OTX-CSI, against dry eye. Ocular Therapeutix also develops intracameral implants for treating multiple eye...
Add to Basket -
Product Insights
NewOcular Therapeutix Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Ocular Therapeutix Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Ocular Therapeutix Inc (Ocular Therapeutix) is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical ocular inflammation and pain. Its pipeline products include OTX-TP, used for treating glaucoma and ocular hypertension; OTX-BPI, targeting acute ocular pain; OTX-BDI, against post-op pain, inflammation and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IVMED-10
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IVMED-10 Drug Details Dexamethasone (IVMED-10) is under development for the treatment of post cataract...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IVMED-20
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IVMED-20 Drug Details IVMED-20 (dexamethasone) is under development for the treatment of high risk...